Vaccine that 'rejuvenates' tired immune cells raises hopes for cancer and dementia patients

British scientists are pioneering a new vaccine that could transform how the body fights age-related diseases by revitalising exhausted immune cells.

The innovative treatment, created by UCL researchers and biotechnology firm SenTcell, targets deteriorated T-cells that accumulate as people grow older.

These white blood cells play a crucial role in orchestrating the body's defensive responses against threats.

The therapy aims to restore the immune system's capacity to identify and combat illnesses, potentially offering new hope for patients battling cancer, HIV and dementia.

TRENDING

Stories

Videos

Your Say

Dr Alessio Lanna at UCL Medicine founded SenTcell to develop this promising approach to immune restoration.

As individuals age or develop chronic conditions, these vital T-cells become increasingly ineffective at coordinating immune protection.

This deterioration leaves people more susceptible to infections and less capable of fighting disease.

The research team believes that resetting these fatigued cells could help restore youthful immune characteristics.

"People living with HIV are now able to live long and healthy lives thanks to major advances in treatment, but many still experience features of accelerated immune ageing. Similar patterns of immune dysfunction are also seen in cancer and other chronic diseases," Dr Lanna said.

"This trial is an important step towards testing whether we can safely rejuvenate exhausted immune cells and restore aspects of healthy immune function."

The scientists are concentrating their efforts on CD4+ T cells, which function as the immune system's directors by guiding other defensive cells to tackle infections and malignancies.

LATEST DEVELOPMENTS:

• 'I'm a nutritionist - your body already makes its own Ozempic if you give it the right foods'
• Nurse who missed her own cancer put symptoms down to football and yoga
• Doctor names the blood clot symptoms missed by half of patients

Within each cell, protective caps called telomeres shield chromosomes from damage, though these structures progressively shrink over time—a recognised indicator of biological ageing.

Laboratory research has indicated that revitalised CD4+ T cells might discharge telomere-containing structures into the blood.

Investigators wish to explore whether this mechanism could explain how renewed immune cells affect tissue health throughout the body.

This concept, however, remains under investigation and has yet to be confirmed in human subjects.

UCL researchers are currently preparing for the Phase 1 clinical trial, which will recruit adult participants experiencing immune dysfunction, including those with immune ageing and chronic viral infections.

Each participant will undergo comprehensive immune profiling both before and after receiving the treatment.

The investigators will assess whether the therapy can restore hallmarks of healthy immune function.

The programme has secured backing through the MHRA's Innovative Licensing and Access Pathway, with researchers hoping to commence trials later this year.

Should the approach prove successful, immune rejuvenation could emerge as a revolutionary treatment strategy—restoring the body's defences rather than targeting individual diseases separately.

Our Standards: The GB News Editorial Charter